CTRI/2022/12/048284已完成2 期
A prospective, randomized, comparative, multi-centric, adaptive design clinicalstudy to evaluate efficacy, safety and tolerability of 101-PGC-005 (‘005) for the treatment of moderate COrona VIrus Disease (Covid-19) disease patients. - NA
AXAI LIFE SCIENCES PVT. LTD.,0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients willing and able to provide voluntary written informed consent and to follow the protocol specific requirements.
- •2. Male or female patients of age 18 to 65 years (both inclusive).
- •3. Patients with ‘moderate’ COVID-19 disease severity, as defined by Comprehensive Guidelines for Management of COVID-19 patients, Directorate General of Health Services, MoHFW, GOI; AND having any of the following symptoms and signs prior
- •to randomization:
- •a. Fever, cough, with or without sore throat/throat irritation, body ache/headache,
- •malaise/weakness, diarrhoea or gastrointestinal upset, with or without anorexia/nausea/vomiting, with or without loss of smell and/or taste, shortness of breath/breathlessness and difficulty in breathing
- •b. Respiratory rate of >24 to <30 breaths/min,
- •c. SpO2: 90 – 93% on room air
- •4. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected within 7 days prior to randomization)
- •5. Elevated CRP, ESR or Ferritin levels
- •6. In case of female patients of child-bearing potential, a negative urine pregnancy test prior to beginning the therapy.
- •7. Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent than the same should be obtained from legally acceptable representative (LAR)
排除标准
- •1. Patients with ‘mild’ or ‘severe’ COVID-19 disease severity, as defined by latest Comprehensive Guidelines for Management of COVID-19 patients, Directorate General of Health Services, MoHFW, GOI at the time of randomization. This includes any one or more of the following
- •a. Peripheral Blood oxygen saturation =94% or <90%
- •b. Respiratory Rate or <24 or =30 breaths per minute
- •2. First positive RT-PCR more than 7 days prior to treatment administration
- •3. Patients with evidence of other serious infectious, malignant, autoimmune, kidney, hepatic, cardiovascular or other systemic disease and/or laboratory abnormality, which, in the opinion of the investigator, prevent the patient from participating in the study
- •4. Subjects with Chronic liver disease (Child Pugh class B or C) and chronic renal disease (GFR <30ml/min).
- •5. Renal dysfunction [Serum Creatinine > 2.5 times of ULN or calculated creatinine clearance < 30ml/min], Liver Dysfunction [Total Bilirubin > 3times ULN & AST/ALT > 5times ULN].
- •6. Chronic systemic glucocorticoid treatment or any immunosuppressive treatment
- •7. History of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- •8. Pregnant and Lactating patients.
- •9. Patients who require IL-6 inhibitors for management of inflammation at the time of study entry.
- •10. Subject has a psychiatric disease that is not well controlled where controlled is defined as: stable on a regimen for more than one year.
- •11. Hospital discharge is anticipated in = 24 hours or anticipated transfer to another hospital which is not a study site within 72 hours.
- •12. Patients that are currently or have participated in such studies participating in other clinical studies with investigational drug, biological agent or device within 1 month or within 5 half-lives (of the drug/biologic) prior to randomization (whichever is longer).
研究者
相似试验
招募中
3 期
A clinical study to determine the efficacy and safety of 101-PGC-005 drug for moderate Corona Virus Disease(Covid-19).CTRI/2024/01/061531axai Life Sciences Pvt Ltd
招募中
3 期
Peg EPO in the Treatment of Anemia due to Chronic Kidney DiseaseCTRI/2013/09/003956Intas Biopharmaceuticals Ltd100
招募中
3 期
A study of Rituximab in patients with Non Hodgkins Lymphoma a type of cancerNHL patientsCTRI/2012/03/002502INTAS BIOPHARMACEUTICALS LTD100
已完成
3 期
A randomized, double-blind, comparative, multicentric, clinical study to evaluate the safety and efficacy of Glucotas Capsules in patients with Prediabetic and Type 2 Diabetes Mellitus.CTRI/2023/09/057720Zoom Technologies Inc217
进行中（未招募）
1 期
A comparative, double-blind, randomised, multicentre efficacy and safety study of ClairYg® versus Tégéline® in maintenance treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Chronic Inflammatory Demyelinating PolyradiculoneuropathyMedDRA version: 15.0Level: PTClassification code 10057645Term: Chronic inflammatory demyelinating polyradiculoneuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-001996-34-FRFB BIOTECHNOLOGIES40